Pemphigus herpetiformis (PH) cases with IgG antibodies to desmocollin 1 (Dsc1) and pemphigoid cases without mucosal involvement reactive with epitopes on various antigens of mucous membrane pemphigoid (MMP) are rare.1- 3 We report a case of coexistence of these 2 bullous diseases.
Correspondence: Dr Hashimoto, Department of Dermatology, Kurume University School of Medicine, and Kurume University Institute of Cutaneous Cell Biology, 67 Asahimachi, Kurume, Fukuoka, 830-0011, Japan (firstname.lastname@example.org).
Conflict of Interest Disclosures: None reported.
Additional Contributions: We gratefully appreciate the secretarial work of Mss Hanako Tomita and Sachika Notomi. We thank the patient for his participation.
Figure 1. Clinical image and hematoxylin-eosin–stained histopathologic specimens from the subject case. A, Skin lesions on the upper extremity. B and C, Biopsy specimen from the right forearm, showing eosinophilic spongiosis (B) (original magnification ×200) and intraepidermal bullae with eosinophils (C) (original magnification ×100). D, Biopsy specimen from the left forearm, showing subepidermal blister with eosinophils (original magnification ×40).
Figure 2. Immunofluorescence and immunoblotting studies of the subject case. A-C, Direct immunofluorescence images for IgG (A), IgA (B), and C3 (C). D, Indirect immunofluorescence of rat bladder for IgG antibodies. E and F, Indirect immunofluorescence of 1M sodium chloride–split skin sections for IgG antibodies (E) and IgA antibodies (F). G, Immunoblotting of recombinant protein of BP180 C-terminal domain, showing positive reactivity by IgG antibodies in control anti-BP180 type mucous membrane pemphigoid (MMP) serum (lane 1) and patient IgG (lane 3) and IgA (weak) (lane 4) antibodies in this case. H, IgG immunoblotting of purified human laminin-332, showing strong reactivity with the α3, β3, and γ2 subunits of laminin-332 for control anti–laminin-332 type MMP (lane 1), and weak reactivity with only the γ2 subunit for this case (lane 3).
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.